A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy

Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation

(2014) H. Shen et al.   JOURNAL OF IMMUNOLOGY

Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells—Significant Roles of CXCL10

(2009) Mitsugu Fujita et al.   CANCER RESEARCH

In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells

(2009) U. K. Scarlett et al.   CANCER RESEARCH

Progress and prospects: immune responses to viral vectors

(2009) S Nayak et al.   GENE THERAPY

New Insights on Adenovirus as Vaccine Vectors

(2009) Marcio O Lasaro et al.   MOLECULAR THERAPY

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

(2009) David Sancho et al.   NATURE

Endotoxin tolerance: new mechanisms, molecules and clinical significance

(2009) Subhra K. Biswas et al.   TRENDS IN IMMUNOLOGY

TLRs and innate immunity

(2008) B. A. Beutler   BLOOD

Using gene transfer to circumvent off-target effects

(2008) C P Miller et al.   GENE THERAPY

Migratory and Lymphoid-Resident Dendritic Cells Cooperate to Efficiently Prime Naive CD4 T cells

(2008) Eric J. Allenspach et al.   IMMUNITY

CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression

(2008) Alexander Michael Dohnal et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE